BioVie (NASDAQ:BIVI) on Monday announced results from two phase 2 trials evaluating its inhibitor NE3107 for the treatment of Parkinson's and Alzheimer's disease.
Class A shares of the clinical-stage company added 9.8% to $5.72 after hours.
According to BIVI, the mid-stage study evaluating NE3107 in Parkinson's met both of its objectives.
"NE3107-treated patients experienced greater motor control in Parkinson's trial," the company said in a statement.
Patients treated with NE3107 also experienced improved cognition and biomarkers in the Alzheimer's trial.
